<!– Name:DistributionId Value:8831004 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1267398 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:798f9390-bcb6-4143-9130-e87d91a3a26e –>
GAITHERSBURG, Md., May 03, 2023 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a digital technology company using machine learning to usher in a new era of precision medicine, today announced that Vin Singh, Chief Executive Officer, will participate in a panel discussion titled “Best Practices and Key Considerations for Successful Deals” at the Pharma Partnering Summit on May 5 in San Diego, California.
“As a leader in the digital health space, I’m honored to join this panel and share my experiences on how to craft successful deals,” said Singh. “This event is a great opportunity for many of us invested in the ‘healthcare meets technology’ world to come together, learn from each other, and discuss best practices that lead to success.”
The Pharma Partnering Summit brings together dealmakers of leading life science companies to create a range of partnering opportunities. The Summit also provides insights on new paradigms for external innovations and disseminates knowledge through expert speakers for the best practices in industry partnerships.
About BullFrog AI
BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek to receive the therapies they need.
For more information visit BullFrogAI at
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
RedChip Companies, Inc.
SOURCE: BullFrog AI Holdings, Inc.